JP4373675B2 - Cb1−拮抗活性を有する4,5−ジヒドロ−1h−ピラゾール誘導体 - Google Patents
Cb1−拮抗活性を有する4,5−ジヒドロ−1h−ピラゾール誘導体 Download PDFInfo
- Publication number
- JP4373675B2 JP4373675B2 JP2002576210A JP2002576210A JP4373675B2 JP 4373675 B2 JP4373675 B2 JP 4373675B2 JP 2002576210 A JP2002576210 A JP 2002576210A JP 2002576210 A JP2002576210 A JP 2002576210A JP 4373675 B2 JP4373675 B2 JP 4373675B2
- Authority
- JP
- Japan
- Prior art keywords
- chlorophenyl
- dihydro
- formula
- phenyl
- pyrazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
上記(4S)−4,5−ジヒドロ−1H−ピラゾールは、精神医学的および神経学的障害の治療のために有用な、強力なカンナビス(Cannabis)−1(CB1)受容体アンタゴニストである。
Mechoulam,R.;Feigenbaum,J.J.Prog.Med.Chem.1987,24,159 Munro,S.;Thomas,K.L.;Abu−Shaar,M.Nature 1993,365,61 Matsuda,L.A.;Bonner,T.I.Cannabinoid Receptors,Pertwee,R.G.Ed.1995,117,Academic Press,London Consroe,P.Neurobiology of Disease 1998,5,534 Pop,E.Curr.Opin.In CPNS Investigational Drugs 1999,1,587 Greenberg,D.A.Drug News Perspect.1999,12,458 Dutta,A.K.;Sard,H.;Ryan,W.;Razdan,R.K.;Compton,D.R.;Martin,B.R.Med.Chem.Res.1994,5,54 Lan,R.;Liu,Q.;Fan,P.;Lin,S.;Fernando,S.R.;McCallion,D.;Pertwee,R.;Makriyannis,A.J.Med.Chem.1999,42,769 Nakamura−Palacios,E.M.;Moerschbaecher,J.M.;Barker,L.A.CNS Drug Rev.1999,5,43 Hosohata,K.;Quock,R,M.;Hosohata,Y.Burkey,T.H.;Makriyannis,A.;Consroe,P.;Roeske,W.R.;Yamamura,H.I.Lite Sc.1997,61,PL115 Felder,C.C.;Joyce,K.E.;Briley,E.J.;Glass,M.;Mackie,K.P.;Fahey,K.J.;Cullinan,G.J.;Hunden,D.C.;Johnson,D.W.;Chaney,M.O.;Koppel,G.A.;Brownstein,M.J.Pharmacol.Exp.Ther.1998,284,291 Kanyonyo,M.;Govaerts,S.J.;Hermans,E.;Poupaert,J.H.,Lambert,D.M.Biorg.Med.Chem.Lett.1999,9,2233 Landsman,R.S.;Burkey,T.H.;Consroe,P.;Roeske,W.R.;Yamamura,H.I.Eur.J.Pharmacol.1997,334,R1 Mechoulam,R.;Hanus,L.;Fride,E.Prog.Med.Chem.1998,35,199 Lambert,D.M.Curr.Med.Chem.1999,6,635 Mechoulam,R.;Fride,E.;Di Marzo,V.Eur.J.Pharmacol.1998,359,1
−RおよびR1は、同じか異なり、そしてハロゲンもしくはメトキシにより置換されていてもよい3−ピリジルもしくは4−ピリジル、またはフェニルを表し、−R2およびR3は、同じか異なり、そして水素、アルキル(1−3C)もしくはジメチルアミノを表し、
−R4は、基ハロゲン、トリフルオロメチル、メトキシおよびアルキル(1−3C)から選ばれる置換基1、2もしくは3個により置換されていてもよいフェニルを表す]
が、対応するR−鏡像異性体よりも、非常に強力で選択的なカンナビスCB1−受容体のアンタゴニストであることが、ここに見い出された。
合成経路A
経路Aの段階1
式(III)
をもつ化合物、例えば2−メチル−2−チオプソイド尿素、または塩基の存在下その適当な塩型との反応。この反応は、式(V)
をもつ4,5−ジヒドロ−1H−ピラゾール−1−カルボキサミジン誘導体を与える。R,R1,R2およびR3が化合物(I)について先に本明細書で記述された意味をもつ式(V)をもつ化合物は新規である。
式(V)をもつ化合物は、場合によっては置換されている式R4−SO2X[式中、R4は、先に述べられた意味をもち、そしてXは、ハロゲン原子を表す]の化合物と反応される。この反応は、好ましくは、非プロトン性溶媒、例えばアセトニトリル中、塩基、例えばトリエチルアミンの存在下で実施される。
経路A1の段階1
式(III)
この反応は、好ましくは、不活性有機溶媒、例えばアセトニトリル中で実施される。
水銀(II)塩、例えばHgCl2の存在下、式(VII)をもつ化合物とアミンとの反応は、式(I)をもつ化合物を与える。
この反応は、好ましくは、極性有機溶媒、例えばアセトニトリル中で実施される。
合成経路A2
経路A2の段階1
式(III)
をもつカルバメートエステル誘導体との反応。
この反応は、式(IX)をもつ4,5−ジヒドロピラゾール−1−カルボキサミド誘導体を与える。R,R1およびR4が、式(I)について先に本明細書で記述された意味をもつ式(IX)をもつ化合物は新規である。
式(IX)をもつ化合物と、ハロゲン化剤、例えばPCl5との反応は、式(X)
をもつ4,5−ジヒドロピラゾール−1−カルボキシミドイルハロゲン化物誘導体を与える。この反応は、好ましくは、不活性有機溶媒、例えばクロロベンゼン中で実施される。R,R1およびR4が、式(I)について先に本明細書で記述された意味をもち、そしてR7がハロゲン原子を表す式(X)をもつ化合物は新規である。
式(X)をもつ化合物とアミンとの反応は、式(I)をもつ化合物を与える。この反応は、好ましくは、不活性有機溶媒、例えばジクロロメタン中で実施される。
経路A3の段階1
式(III)
をもつジチオイミド炭酸エステル誘導体との反応。
この反応は、好ましくは、極性有機溶媒、例えばアセトニトリル中で実施される。
R,R1およびR4が、式(I)について先に本明細書で記述された意味をもち、そしてR8がC1−3アルキル基を表す式(XII)をもつ化合物は新規である。
式(XII)をもつ化合物とアミンとの反応は、式(I)をもつ化合物を与える。
この反応は、好ましくは、極性有機溶媒、例えばメタノール中で実施される。
パートA: 3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール(5.13g,20.0mmol)、2−メチル−2−チオプソイド尿素ヨウ素酸塩(5.00g,23.0mmol)およびピリジン(10ml)の撹拌混合液を、110℃において1時間加熱する。室温で一夜放置後、ジエチルエーテルを添加し、そして沈殿を濾過によって回収する。この沈殿を、一定分量のジエチルエーテルで3回洗浄して固形物(9g)を得る。融点:〜230℃。この固形物をメタノール(20ml)に溶解する。得られる溶液に、続いて2N水酸化ナトリウム溶液(12ml)および水(200ml)を連続して添加する。形成した沈殿を濾過によって回収し、ジエチルエーテルで2回、続いてジイソプロピルエーテルで洗浄する。得られる固形物を真空乾燥して、3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン(5.1g,収率88%)を得る。融点:187−189℃。
4,5−ジヒドロ−N−((4−フルオロフェニル)スルホニル)−3−(4−メトキシフェニル)−4−(4−メトキシフェニル)−1H−ピラゾール−1−カルボキサミジン:融点:155−156℃
4,5−ジヒドロ−3−(4−メトキシフェニル)−4−(4−メトキシフェニル)−N−((4−メトキシフェニル)スルホニル)−1H−ピラゾール−1−カルボキサミジン:融点:148−150℃
3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−N−((2,4,6−トリメチルフェニル)スルホニル)−1H−ピラゾール−1−カルボキサミジン−カルボキサミジン:融点:221−222℃。
実施例II
パートA: アセトニトリル(200ml)中3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール(12.0g,46.8mmol)、[(4−クロロフェニル)スルホニル]ジチオイミド炭酸ジメチルエステル(CAS:13068−12−7)(9.20g,31.1mmol)およびトリエチルアミン(15ml)の撹拌混合液を、還流温度において20時間加熱する。さらなる分量の3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール(12.0g,46.8mmol)を添加し、そして得られる混合液を還流温度においてさらに16時間加熱する。真空濃縮後、ジクロロメタンを添加し、そして得られる溶液を水で2回洗浄し、無水Na2SO4で乾燥する。濾過および真空蒸発後、残渣を、さらにフラッシュクロマトグラフィー(ジエチルエーテル/石油エーテル=1/1(v/v))によって精製して、3−(4−クロロフェニル)−N−((4−クロロフェニル)スルホニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキシミドチオ酸メチルエステル(12.5g,[(4−クロロフェニル)スルホニル]ジチオイミド炭酸ジメチルエステルに基づいて収率80%)を無定形固体として得る。
N−メチル−N’−((4−クロロフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−(3−ピリジル)−1H−ピラゾール−1−カルボキサミジン.融点:101−105℃.
N−メチル−N’−((4−クロロフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−(4−ピリジル)−1H−ピラゾール−1−カルボキサミジン.融点:112−115℃.
実施例III
パートA: 1,4−ジオキサン(20ml)中N−((4−クロロフェニル)スルホニル)カルバミン酸メチルエステル(CAS:34543−04−9)(2.99g,12.0mmol)およびピリジン(4ml)の溶液に、3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール(3.39g,13.2mmol)を添加し、そして得られる混合液を100℃において4時間撹拌する。真空濃縮後、残渣をジクロロメタンに溶解し、続いて水、1NHClおよび水で洗浄し、無水Na2SO4で乾燥し、濾過し、そして容量20mlまで真空濃縮する。メチル−tert−ブチルエーテル(60ml)を添加し、そして得られる溶液を容量20mlまで濃縮する。形成した結晶を濾過によって回収し、そしてメチル−tert−ブチルエーテルから再結晶化して、3−(4−クロロフェニル)−N−((4−クロロフェニル)スルホニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミド(4.75g,収率76%)を得る。融点:211−214℃。
N−メチル−N’−((3−クロロフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン.融点:156−160℃.
N−プロピル−N’−((4−フルオロフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン.融点:129−138℃.
N−(2−プロピル)−N’−((4−フルオロフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン.融点:110−112℃.
N−(2−プロピル)−N’−((4−クロロフェニル)スルホニル)−3−(4−ピリジル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン.融点:無定形.
N1−エチル−N1−メチル−N2−((4−クロロフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン.融点:184℃.
N1−エチル−N1−メチル−N2−((4−フルオロフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン.融点:173−176℃.
N1,N1−ジメチル−N2−((4−(トリフルオロメチル)フェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン.融点:195−196℃.
N1,N1−ジメチル−N2−((3−メチルフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン.融点:195−198℃.
N1,N1−ジメチル−N2−((3−メトキシフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン.融点:204−206℃.
N−エチル−N’−((4−クロロフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン.融点:無定形.
N−ジメチルアミノ−N’−((4−クロロフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン.融点:155−159℃.
N−メチル−N’−((4−(トリフルオロメチル)フェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン.融点:無定形.
N1,N1−ジメチル−N2−((2−メチルフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン.融点:148−151℃.
N−メチル−N’−((2,4−ジフルオロフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン.融点:85℃.
実施例IV
(−)−(4S)−N−メチル−N’−((4−クロロフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン(7.16g,0.0147mol))([α25 D]=−150°,c=0.01,MeOH)(融点:169−170℃)を、ChiralpakAD,20μmキラル固定相を用いる、ラセミN−メチル−N’−((4−クロロフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン(18g,0.037mol)のキラルクロマトグラフィー分離をとおして得た。移動相は、ヘキサン/エタノール(80/20(v/v))および0.1%水酸化アンモニウム(25%水溶液)の混合液からなった。
(−)−(4S)−N−エチル−N’−((4−クロロフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン:([α25 D]=−126°,c=0.01,CHCl3);融点:172−175℃.固定相:ChiralcelOD.移動相:ヘプタン/2−プロパノール混合液(85/15(v/v)).
(−)−(4S)−N−ジメチルアミノ−N’−((4−クロロフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン:([α25 D]=−132°,c=0.01,CHCl3);融点:218−224℃.固定相:ChiralcelOD.移動相:ヘプタン/2−プロパノール混合液(85/15(v/v)). (−)−(4S)−N−メチル−N’−((4−(トリフルオロメチル)フェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン:([α25 D]=−131°,c=0.01,CHCl3);融点:157−160℃.固定相:ChiralcelOD.移動相:ヘプタン/2−プロパノール混合液(85/15(v/v)).
(−)−(4S)−N1,N1−ジメチル−N2−((2−メチルフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン:([α25 D]=−88°,c=0.01,MeOH);融点:無定形.固定相:ChiralpakAD.移動相:エタノール.
(−)−(4S)−N−メチル−N’−((2,4−ジフルオロフェニル)スルホニル)−3−(4−クロロフェニル)−4,5−ジヒドロ−4−フェニル−1H−ピラゾール−1−カルボキサミジン:([α25 D]=−129°,c=0.01,MeOH);融点:無定形.固定相:ChiralpakAD.移動相:メタノール.
Claims (3)
- Rが4−クロロフェニルであり、R1がフェニルであり、R2が水素であり、R3がメチルであり、そしてR4が4−クロロフェニルを表す、請求項1において請求される式(I)をもつ化合物、およびその塩。
- 請求項1に記載の式Iをもつ化合物のラセミ混合物が、左旋性および右旋性鏡像異性体に分離されることを特徴とする、請求項1に記載の式Iをもつ化合物の製造方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01201062 | 2001-03-22 | ||
PCT/EP2002/003079 WO2002076949A1 (en) | 2001-03-22 | 2002-03-18 | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004518763A JP2004518763A (ja) | 2004-06-24 |
JP2004518763A5 JP2004518763A5 (ja) | 2005-12-22 |
JP4373675B2 true JP4373675B2 (ja) | 2009-11-25 |
Family
ID=8180044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002576210A Expired - Fee Related JP4373675B2 (ja) | 2001-03-22 | 2002-03-18 | Cb1−拮抗活性を有する4,5−ジヒドロ−1h−ピラゾール誘導体 |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP1373216B1 (ja) |
JP (1) | JP4373675B2 (ja) |
KR (1) | KR100846614B1 (ja) |
CN (1) | CN100366614C (ja) |
AR (1) | AR033046A1 (ja) |
AT (1) | ATE284872T1 (ja) |
AU (1) | AU2002256690B2 (ja) |
BR (1) | BR0205602A (ja) |
CA (1) | CA2422708C (ja) |
CZ (1) | CZ2003698A3 (ja) |
DE (1) | DE60202270T2 (ja) |
ES (1) | ES2229132T3 (ja) |
HK (1) | HK1061852A1 (ja) |
HU (1) | HUP0303148A3 (ja) |
IL (1) | IL153508A (ja) |
MX (1) | MXPA03003534A (ja) |
NO (1) | NO324953B1 (ja) |
NZ (1) | NZ524633A (ja) |
PL (1) | PL363751A1 (ja) |
PT (1) | PT1373216E (ja) |
RU (1) | RU2281941C2 (ja) |
SI (1) | SI1373216T1 (ja) |
SK (1) | SK287592B6 (ja) |
UA (1) | UA74066C2 (ja) |
WO (1) | WO2002076949A1 (ja) |
ZA (1) | ZA200307322B (ja) |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
CA2478183C (en) | 2002-03-12 | 2010-02-16 | Merck & Co. Inc. | Substituted amides |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
TW200511990A (en) * | 2003-09-02 | 2005-04-01 | Solvay Pharm Gmbh | Novel medical uses of 4, 5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
WO2005028438A1 (ja) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
WO2005039550A2 (en) * | 2003-10-24 | 2005-05-06 | Solvay Pharmaceuticals Gmbh | Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds |
AR046132A1 (es) * | 2003-10-24 | 2005-11-23 | Solvay Pharm Gmbh | Composicin farmaceutica que contiene al menos un compuesto con actividad de receptor de cb1, o un profarmaco , tautomero o sal del mismo, como componente activo adecuado para el tratamiento y/o profilaxis de enfermedades relacionadas con el receptor cb1 en pacientes juveniles y/o para el tratamiento |
WO2005049615A1 (en) * | 2003-11-21 | 2005-06-02 | Pfizer Products Inc. | Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists |
ATE478856T1 (de) | 2004-01-28 | 2010-09-15 | Hoffmann La Roche | Spirobenzodioxole und deren verwendung als cb1- antagonisten |
MXPA06008593A (es) * | 2004-01-30 | 2006-08-28 | Solvay Pharm Bv | Derivados 1,3,5-trisustituidos de 4,5-dihidro-1h-pirazol que tienen actividad antagonista del receptor canabinoide 1. |
US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
WO2005097759A1 (en) | 2004-03-29 | 2005-10-20 | Merck & Co., Inc. | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
JP2008509146A (ja) | 2004-08-06 | 2008-03-27 | メルク エンド カムパニー インコーポレーテッド | 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ−1の阻害剤としてのスルホニル化合物 |
EP1784390A2 (en) | 2004-08-13 | 2007-05-16 | Amgen Inc. | Substituted benzofused heterocycles |
EP1807063A2 (en) * | 2004-10-25 | 2007-07-18 | Solvay Pharmaceuticals GmbH | Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
US20090156474A1 (en) | 2004-11-01 | 2009-06-18 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity and obesity related diseases and disorders |
ES2351348T3 (es) | 2004-11-09 | 2011-02-03 | F. Hoffmann-La Roche Ag | Derivados de la dibenzosuberona. |
WO2006060186A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Pyrazole derivatives for the treatment of dementia and related disorders |
WO2006060201A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Pyrazole derivatives for the treatment of psychiatric disorders |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
KR101397913B1 (ko) | 2005-05-30 | 2014-05-26 | 엠에스디 가부시키가이샤 | 신규 피페리딘 유도체 |
JP2008545739A (ja) | 2005-06-02 | 2008-12-18 | グレンマーク・ファーマシューティカルズ・エスエー | 新規なカンナビノイド受容体リガンド、それらを含む薬剤組成物、およびそれらの調製方法 |
US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
EP1757587A1 (en) * | 2005-07-15 | 2007-02-28 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
WO2007018248A1 (ja) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | ピリドン化合物 |
CA2617649A1 (en) | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
AU2006282260A1 (en) | 2005-08-24 | 2007-03-01 | Msd K.K. | Phenylpyridone derivative |
EP1940842B1 (en) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
US8163770B2 (en) | 2005-10-27 | 2012-04-24 | Msd. K. K. | Benzoxathiin derivative |
KR101318127B1 (ko) | 2005-11-10 | 2013-10-16 | 엠에스디 가부시키가이샤 | 아자 치환된 스피로 유도체 |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
EP1801098A1 (en) | 2005-12-16 | 2007-06-27 | Merck Sante | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors |
KR101036981B1 (ko) | 2006-02-23 | 2011-05-25 | 화이자 리미티드 | 멜라노코르틴 제4형 수용체 효능제 피페리디노일피롤리딘 |
US7763607B2 (en) | 2006-04-27 | 2010-07-27 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators |
CN101431998A (zh) * | 2006-04-27 | 2009-05-13 | 索尔瓦药物有限公司 | 含有CBx大麻素受体调节剂和钾通道调节剂的药物组合物 |
MX2009001043A (es) | 2006-08-08 | 2009-02-06 | Sanofi Aventis | Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso. |
WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
EP2072519A4 (en) | 2006-09-28 | 2009-10-21 | Banyu Pharma Co Ltd | DIARYLKETIMINDERIVAT |
KR20090064478A (ko) | 2006-11-13 | 2009-06-18 | 화이자 프로덕츠 인크. | 디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도 |
US8404896B2 (en) | 2006-12-01 | 2013-03-26 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
EP1935420A1 (en) | 2006-12-21 | 2008-06-25 | Merck Sante | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors |
US8106086B2 (en) | 2007-04-02 | 2012-01-31 | Msd K.K. | Indoledione derivative |
WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
CN101318931B (zh) * | 2007-06-04 | 2010-05-19 | 上海阳帆医药科技有限公司 | 二芳基取代吡唑衍生物、其制备方法和用途 |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
GB2456183A (en) * | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
CA2714617A1 (en) | 2008-03-06 | 2009-09-11 | Banyu Pharmaceutical Co., Ltd. | Alkylaminopyridine derivative |
CN101981025A (zh) | 2008-03-28 | 2011-02-23 | 万有制药株式会社 | 具有黑色素浓缩激素受体拮抗作用的二芳基甲基酰胺衍生物 |
EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
JPWO2009154132A1 (ja) | 2008-06-19 | 2011-12-01 | Msd株式会社 | スピロジアミン−ジアリールケトオキシム誘導体 |
AR072707A1 (es) | 2008-07-09 | 2010-09-15 | Sanofi Aventis | Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos |
WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
EP2319841A1 (en) | 2008-07-30 | 2011-05-11 | Msd K.K. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
ES2421920T3 (es) | 2008-08-06 | 2013-09-06 | Pfizer Ltd | Compuestos de diazepina y diazocano como agonistas de MC4 |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EA201170624A1 (ru) | 2008-10-30 | 2011-12-30 | Мерк Шарп Энд Домэ Корп. | Изоникотинамидные антагонисты рецепторов орексинов |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
JP5514831B2 (ja) | 2008-11-17 | 2014-06-04 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病の治療のための置換二環式アミン |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
ES2443016T3 (es) | 2009-08-26 | 2014-02-17 | Sanofi | Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo |
CN102812011A (zh) | 2009-11-16 | 2012-12-05 | 梅利科技公司 | [1,5]-二氮杂环辛间四烯衍生物 |
US8648073B2 (en) | 2009-12-30 | 2014-02-11 | Fochon Pharma, Inc. | Certain dipeptidyl peptidase inhibitors |
AR079935A1 (es) | 2010-01-29 | 2012-02-29 | Abbott Healthcare Products Bv | Sintesis de derivados de pirazolin carboxamidina sustituida |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8785634B2 (en) | 2010-04-26 | 2014-07-22 | Merck Sharp & Dohme Corp | Spiropiperidine prolylcarboxypeptidase inhibitors |
WO2011143057A1 (en) | 2010-05-11 | 2011-11-17 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
US9006268B2 (en) | 2010-06-11 | 2015-04-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CN103476258B (zh) | 2011-02-25 | 2017-04-26 | 默沙东公司 | 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物 |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
US8680131B2 (en) * | 2012-07-25 | 2014-03-25 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers |
EP2880028B1 (en) | 2012-08-02 | 2020-09-30 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US11155521B2 (en) | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
CN104884057B (zh) | 2012-11-13 | 2019-08-20 | 美国政府(由卫生和人类服务部的部长所代表) | 大麻素受体介导的化合物 |
CA2898482A1 (en) | 2013-02-22 | 2014-08-28 | Linda L. Brockunier | Antidiabetic bicyclic compounds |
EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
CA2913737A1 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CA2948349C (en) | 2014-05-09 | 2023-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pyrazole derivatives and their use as cannabinoid receptor mediators |
KR102431436B1 (ko) | 2014-08-29 | 2022-08-10 | 테스 파마 에스.알.엘. | α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제 |
CN108699043A (zh) * | 2016-03-04 | 2018-10-23 | 美国政府(由卫生和人类服务部的部长所代表) | 大麻素受体介导化合物 |
WO2018069532A1 (en) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
AU2019385644A1 (en) | 2018-11-20 | 2021-06-03 | Tes Pharma S.R.L. | Inhibitors of α-Amino-β-carboxymuconic acid semialdehyde decarboxylase |
EP3924058A1 (en) | 2019-02-13 | 2021-12-22 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
US20230018413A1 (en) | 2019-08-08 | 2023-01-19 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
TW202227417A (zh) | 2020-08-18 | 2022-07-16 | 美商默沙東藥廠 | 雙環庚烷吡咯啶之食慾素受體促效劑 |
EP4341246A1 (en) * | 2021-05-17 | 2024-03-27 | The United States of America, as represented by The Secretary, Department of Health and Human Services | A facile and odor-free approach to convert sulfonyl urea derivatives to chalcogenide sulfonyl urea derivatives |
WO2023196556A1 (en) * | 2022-04-07 | 2023-10-12 | Corbus Pharmaceuticals, Inc. | Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL158178B (nl) * | 1974-07-12 | 1978-10-16 | Philips Nv | Werkwijze ter bereiding van insekticide preparaten die een pyrazolinederivaat bevatten, aldus verkregen gevormde preparaten, en werkwijze ter bereiding van pyrazolinederivaten met insekticide werking. |
DE3431926A1 (de) * | 1984-08-30 | 1986-03-06 | Bayer Ag, 5090 Leverkusen | Amidinoazole |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
MXPA02009258A (es) * | 2000-03-23 | 2005-04-19 | Solvay Pharm Bv | Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonistica de cannabis-1. |
PE20021046A1 (es) * | 2000-09-30 | 2002-12-14 | Gruenenthal Chemie | Sulfonilguanidina que tiene afinidad al punto de fijacion de gabapentina |
-
2002
- 2002-03-18 EP EP02726190A patent/EP1373216B1/en not_active Expired - Lifetime
- 2002-03-18 KR KR1020027018040A patent/KR100846614B1/ko not_active IP Right Cessation
- 2002-03-18 RU RU2003105900/04A patent/RU2281941C2/ru not_active IP Right Cessation
- 2002-03-18 PL PL02363751A patent/PL363751A1/xx not_active IP Right Cessation
- 2002-03-18 WO PCT/EP2002/003079 patent/WO2002076949A1/en active IP Right Grant
- 2002-03-18 AU AU2002256690A patent/AU2002256690B2/en not_active Ceased
- 2002-03-18 CA CA2422708A patent/CA2422708C/en not_active Expired - Fee Related
- 2002-03-18 JP JP2002576210A patent/JP4373675B2/ja not_active Expired - Fee Related
- 2002-03-18 AT AT02726190T patent/ATE284872T1/de active
- 2002-03-18 IL IL153508A patent/IL153508A/en not_active IP Right Cessation
- 2002-03-18 CZ CZ2003698A patent/CZ2003698A3/cs unknown
- 2002-03-18 BR BR0205602-0A patent/BR0205602A/pt not_active Application Discontinuation
- 2002-03-18 SK SK308-2003A patent/SK287592B6/sk not_active IP Right Cessation
- 2002-03-18 CN CNB028017773A patent/CN100366614C/zh not_active Expired - Fee Related
- 2002-03-18 ES ES02726190T patent/ES2229132T3/es not_active Expired - Lifetime
- 2002-03-18 DE DE60202270T patent/DE60202270T2/de not_active Expired - Lifetime
- 2002-03-18 MX MXPA03003534A patent/MXPA03003534A/es active IP Right Grant
- 2002-03-18 PT PT02726190T patent/PT1373216E/pt unknown
- 2002-03-18 HU HU0303148A patent/HUP0303148A3/hu unknown
- 2002-03-18 SI SI200230065T patent/SI1373216T1/xx unknown
- 2002-03-18 AR ARP020100954A patent/AR033046A1/es unknown
- 2002-03-18 NZ NZ524633A patent/NZ524633A/en unknown
- 2002-03-18 UA UA2003109493A patent/UA74066C2/uk unknown
-
2003
- 2003-06-23 NO NO20032892A patent/NO324953B1/no not_active IP Right Cessation
- 2003-09-18 ZA ZA200307322A patent/ZA200307322B/en unknown
-
2004
- 2004-07-06 HK HK04104848A patent/HK1061852A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4373675B2 (ja) | Cb1−拮抗活性を有する4,5−ジヒドロ−1h−ピラゾール誘導体 | |
US6476060B2 (en) | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | |
JP4313671B2 (ja) | Cb1−拮抗活性を有する新規4,5−ジヒドロ−1h−ピラゾール誘導体 | |
AU2002256690A1 (en) | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | |
AU2002333853B2 (en) | 4,5-dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity | |
AU2002333853A1 (en) | 4,5-dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity | |
AU2002333852A1 (en) | Novel 4,5-dihydro-1H-pyrazole derivativeshaving CB1-antagonistic activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041015 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041015 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080202 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20080730 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080805 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081021 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081028 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090113 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090408 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090519 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090803 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090901 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090904 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120911 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |